Published by mark itwired
Posted on September 9, 2021
10 min readLast updated: February 12, 2026
Add as preferred source on Google
By drug class, opioids are widely used analgesic drugs for treating moderate to severe pain such as pain caused by surgery, cancer, trauma, injury, and other diseases. Owing to their high efficiency and widespread availability in the developed markets of North America and Western Europe, opioids are a high revenue generating segment in the global analgesics market. In a new research publication, leading market research firm Future Market Insights presents forecasts on revenue generated from the sales of branded and generic analgesic drugs including opioids, non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and local anaesthetics.
According to Future Market Insights’ projections, the global prescription analgesics market is anticipated to reach a whopping US$ 79 Bn by 2028 end, up from an estimated US$ 47.5 Bn in 2018. This is indicative of a CAGR of 5.3% during the 10 year period from 2018 to 2028. This growth is mainly contributed by the regional markets in North America and Western Europe that are projected to collectively hold a revenue share of just under 71% in 2018.
Following the U.S opioid crisis, several countries across the globe are introducing regulations pertaining to the prescription of opioids. To curb the growing abuse of painkilling drugs, pharma companies are introducing different types of abuse deterrent drugs in the global market. Opioids are widely used for pain management in North America and Europe and are being increasingly used for non-medical purposes as well. Government organizations in these economies are encouraging doctors to prescribe non-opioid analgesics. This is slated to create significant growth opportunities for companies to introduce novel non-opioid drugs in these markets. The situation in the countries of Asia and Africa is different – the limited availability of both opioid and non-opioid drug delivery systems for pain management provides immense opportunities to manufacturers of analgesics for regional market penetration.
Opioid intolerance is a new phenomenon that has hit the pharmaceuticals industry in North America and Europe. Opioids are ineffective in treating certain cases of severe pain, necessitating patients to take higher doses to alleviate the pain. This eventually makes them opioid intolerant or addicted to these drugs. Commercializing opioid tolerant drugs is the most viable solution that will help reduce the side effects associated with increasing consumption of opioids. Manufacturers in the global analgesics market are expected to benefit from the numerous opportunities presented by the commercialization of opioid tolerant drugs.
Request For Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1306
Key players in the global analgesics market are focused on R&D initiatives to develop non-opioid drugs using innovative drug delivery approaches to facilitate extended release of the medication, which can provide pain relief for a longer time duration. Pharmaceutical companies are also launching cost-efficient opioid drugs in Asian countries and this is expected to boost revenue growth in the global market for analgesics. Commercial expansion of products across potential growth markets in Asia and Africa is a feasible strategy being adopted by manufacturers of analgesics to expand their global market footprint.
Opioids are largely used in palliative care for treating terminally ill patients. There is a growing focus on palliative care services across third world countries. This – coupled with readily available reimbursement options – is expected to boost the consumption of opioids in the coming decade. Several government initiatives to promote palliative care among patients suffering from cancer pain in low and middle income countries are promoting the adoption of opioids as an effective pain management solution.
Another trend being observed in the global market is the use of Opioids Maintenance Treatment (OMT) to treat Opioids Dependence (OD). The main objective of OMT is to reduce patients’ addiction to consume illicit drugs that are used to reduce opioid dependency. While there are certain controversies associated with the commercialization of OMT (it is claimed that OMT is another form of addiction), these drugs are highly regulated and the concerned governments are implementing stringent regulations to prevent abuse of these drugs.
Download TOC @ https://www.futuremarketinsights.com/reports/analgesics-market/table-of-content
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2.1. Market Taxonomy
2.2. Market Definition
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
4.1. Market Dynamics
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Trends
5.1. Gross Domestic Product by Region & Country, 2006 – 2021
6.1. PEST Analysis
6.2. Key Regulations: Opioids
6.3. Opioid Consumption : Fast Fact
7.1. Introduction
7.2. Historical Market Value (US$ Mn) Analysis By Country, 2013–2017
7.2.1. U.S.
7.2.2. Canada
7.3. Market Value (US$ Mn) Forecast By Country, 2018–2028
7.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2013–2017
7.4.1. Opioids
7.4.2. NSAIDs
7.4.3. Local Anesthetics
7.4.4. Acetaminophen
7.5. Market Value (US$ Mn) Forecast By Drug Class, 2018–2028
7.6. Historical Market Value (US$ Mn) Trend Analysis By Pain Type, 2013–2017
7.6.1. Surgical Pain
7.6.2. Cancer Pain
7.6.3. Neuropathic Pain
7.6.4. Others
7.7. Market Value (US$ Mn) Forecast By Pain Type, 2018–2028
7.8. Historical Market Value (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
7.8.1. Injectable
7.8.2. Oral
7.8.3. Topical
7.8.4. Transdermal
7.8.5. Others
7.9. Market Value (US$ Mn) Forecast By Route of Administration, 2018–2028
The post The Global Analgesics Market is expected to expand at a CAGR of 5.0% at end of 2028 first appeared on Market Research Blog.
By drug class, opioids are widely used analgesic drugs for treating moderate to severe pain such as pain caused by surgery, cancer, trauma, injury, and other diseases. Owing to their high efficiency and widespread availability in the developed markets of North America and Western Europe, opioids are a high revenue generating segment in the global analgesics market. In a new research publication, leading market research firm Future Market Insights presents forecasts on revenue generated from the sales of branded and generic analgesic drugs including opioids, non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and local anaesthetics.
According to Future Market Insights’ projections, the global prescription analgesics market is anticipated to reach a whopping US$ 79 Bn by 2028 end, up from an estimated US$ 47.5 Bn in 2018. This is indicative of a CAGR of 5.3% during the 10 year period from 2018 to 2028. This growth is mainly contributed by the regional markets in North America and Western Europe that are projected to collectively hold a revenue share of just under 71% in 2018.
Following the U.S opioid crisis, several countries across the globe are introducing regulations pertaining to the prescription of opioids. To curb the growing abuse of painkilling drugs, pharma companies are introducing different types of abuse deterrent drugs in the global market. Opioids are widely used for pain management in North America and Europe and are being increasingly used for non-medical purposes as well. Government organizations in these economies are encouraging doctors to prescribe non-opioid analgesics. This is slated to create significant growth opportunities for companies to introduce novel non-opioid drugs in these markets. The situation in the countries of Asia and Africa is different – the limited availability of both opioid and non-opioid drug delivery systems for pain management provides immense opportunities to manufacturers of analgesics for regional market penetration.
Opioid intolerance is a new phenomenon that has hit the pharmaceuticals industry in North America and Europe. Opioids are ineffective in treating certain cases of severe pain, necessitating patients to take higher doses to alleviate the pain. This eventually makes them opioid intolerant or addicted to these drugs. Commercializing opioid tolerant drugs is the most viable solution that will help reduce the side effects associated with increasing consumption of opioids. Manufacturers in the global analgesics market are expected to benefit from the numerous opportunities presented by the commercialization of opioid tolerant drugs.
Request For Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1306
Key players in the global analgesics market are focused on R&D initiatives to develop non-opioid drugs using innovative drug delivery approaches to facilitate extended release of the medication, which can provide pain relief for a longer time duration. Pharmaceutical companies are also launching cost-efficient opioid drugs in Asian countries and this is expected to boost revenue growth in the global market for analgesics. Commercial expansion of products across potential growth markets in Asia and Africa is a feasible strategy being adopted by manufacturers of analgesics to expand their global market footprint.
Opioids are largely used in palliative care for treating terminally ill patients. There is a growing focus on palliative care services across third world countries. This – coupled with readily available reimbursement options – is expected to boost the consumption of opioids in the coming decade. Several government initiatives to promote palliative care among patients suffering from cancer pain in low and middle income countries are promoting the adoption of opioids as an effective pain management solution.
Another trend being observed in the global market is the use of Opioids Maintenance Treatment (OMT) to treat Opioids Dependence (OD). The main objective of OMT is to reduce patients’ addiction to consume illicit drugs that are used to reduce opioid dependency. While there are certain controversies associated with the commercialization of OMT (it is claimed that OMT is another form of addiction), these drugs are highly regulated and the concerned governments are implementing stringent regulations to prevent abuse of these drugs.
Download TOC @ https://www.futuremarketinsights.com/reports/analgesics-market/table-of-content
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2.1. Market Taxonomy
2.2. Market Definition
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
4.1. Market Dynamics
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Trends
5.1. Gross Domestic Product by Region & Country, 2006 – 2021
6.1. PEST Analysis
6.2. Key Regulations: Opioids
6.3. Opioid Consumption : Fast Fact
7.1. Introduction
7.2. Historical Market Value (US$ Mn) Analysis By Country, 2013–2017
7.2.1. U.S.
7.2.2. Canada
7.3. Market Value (US$ Mn) Forecast By Country, 2018–2028
7.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2013–2017
7.4.1. Opioids
7.4.2. NSAIDs
7.4.3. Local Anesthetics
7.4.4. Acetaminophen
7.5. Market Value (US$ Mn) Forecast By Drug Class, 2018–2028
7.6. Historical Market Value (US$ Mn) Trend Analysis By Pain Type, 2013–2017
7.6.1. Surgical Pain
7.6.2. Cancer Pain
7.6.3. Neuropathic Pain
7.6.4. Others
7.7. Market Value (US$ Mn) Forecast By Pain Type, 2018–2028
7.8. Historical Market Value (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
7.8.1. Injectable
7.8.2. Oral
7.8.3. Topical
7.8.4. Transdermal
7.8.5. Others
7.9. Market Value (US$ Mn) Forecast By Route of Administration, 2018–2028
The post The Global Analgesics Market is expected to expand at a CAGR of 5.0% at end of 2028 first appeared on Market Research Blog.
An analgesic is a type of medication used to relieve pain. They can be classified into various categories, including opioids and non-steroidal anti-inflammatory drugs (NSAIDs), and are commonly prescribed for conditions such as surgery, cancer, and injury.
Opioids are a class of drugs that are used to treat moderate to severe pain. They work by binding to specific receptors in the brain and body to reduce the perception of pain.
CAGR stands for Compound Annual Growth Rate. It is a useful measure to understand the mean annual growth rate of an investment over a specified time period, assuming the investment grows at a steady rate.
NSAIDs are a class of medications that provide pain relief, reduce inflammation, and lower fever. Common examples include ibuprofen and aspirin, and they are often used for conditions like arthritis and muscle pain.
Explore more articles in the Research Reports category
